Nephronomics

Nephronomics is a precision medicine biotechnology company that operates as a joint venture with Fresenius Medical Care. The company utilizes a proprietary data and analytics platform, referred to as the Nephronomics Atlas, which integrates longitudinal clinical and genomic data from over 42,000 consented patients with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD). By employing advanced machine learning models, the company analyzes these datasets—which include laboratory results, diagnosis histories, treatment records, and radiology images—to identify molecular mechanisms and disease patterns for cardio-kidney-metabolic (CKM) conditions.

This technology platform serves to support research and the development of targeted therapies and next-generation diagnostics for patients with CKM disorders. By providing a deeper understanding of the underlying biology linked to the intersection of cardiovascular, kidney, and metabolic health, Nephronomics aims to transform disease care. The company’s approach is supported by venture capital backing and strategic leadership, enabling it to bridge clinical access with computational biology to advance precision medicine in the renal and metabolic research sectors.